{"transactions":[{"id":751231,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:48:33.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040583","document":"wk-form4_1780530511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040583/wk-form4_1780530511.xml","form_type":"4"}},{"id":765978,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:05.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001730615-26-000003","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000173061526000003/ownership.xml","form_type":"4"}},{"id":932215,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:37:09.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":26550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":5.79,"underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0000905148-26-000324","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000324/form4.xml","form_type":"4"}},{"id":932214,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:37:09.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":14100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":9.18,"underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000905148-26-000324","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000324/form4.xml","form_type":"4"}},{"id":932213,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:37:09.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":14100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":11.35,"underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000905148-26-000324","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000324/form4.xml","form_type":"4"}},{"id":932212,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:37:09.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":8333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":3,"underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0000905148-26-000324","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000324/form4.xml","form_type":"4"}},{"id":932211,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:37:09.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":14166,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."}],"balance_after":0,"derivative":{"exercise_price":12.24,"underlying":"Common Stock","underlying_shares":14166},"source":{"system":"sec-edgar","filing":"0000905148-26-000324","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000324/form4.xml","form_type":"4"}},{"id":932210,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-01-23T16:37:09.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":263321,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly-owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000905148-26-000324","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000324/form4.xml","form_type":"4"}},{"id":1103558,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:46:20.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061818","document":"tm2518376-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061818/tm2518376-15_4seq1.xml","form_type":"4"}},{"id":1113251,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T19:11:30.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":26550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":26550,"derivative":{"exercise_price":5.79,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0001104659-25-059031","document":"tm2517800-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465925059031/tm2517800-3_4seq1.xml","form_type":"4"}},{"id":1137209,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T20:44:50.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-25-076412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076412/ownership.xml","form_type":"4"}},{"id":1488309,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:06:56.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2024 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":14100,"derivative":{"exercise_price":9.18,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001104659-24-069074","document":"tm2416582-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924069074/tm2416582-5_4seq1.xml","form_type":"4"}},{"id":1500438,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T00:02:21.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":11000,"derivative":{"exercise_price":21.77,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000950170-24-065560","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024065560/ownership.xml","form_type":"4"}},{"id":1782083,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-14T01:25:41.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":6500,"derivative":{"exercise_price":11.2,"expiration_date":"2033-09-10","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0000899243-23-018869","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924323018869/doc4.xml","form_type":"4"}},{"id":1865097,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T08:06:13.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":14100,"derivative":{"exercise_price":11.35,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001104659-23-068340","document":"tm2317752-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465923068340/tm2317752-7_4seq1.xml","form_type":"4"}},{"id":2028050,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T23:35:01.000Z","date":"2023-02-02","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":239205,"derivative":{"exercise_price":0.15,"expiration_date":"2030-09-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-004233","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924323004233/doc4a.xml","form_type":"4/A","original_submission_date":"2023-02-07"}},{"id":2028049,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-07T23:35:01.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":50000,"price":36.8,"value":1840000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":480905,"source":{"system":"sec-edgar","filing":"0000899243-23-004233","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924323004233/doc4a.xml","form_type":"4/A","original_submission_date":"2023-02-07"}},{"id":2028048,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-07T23:35:01.000Z","date":"2023-02-02","kind":"exercise","acquired":true,"shares":50000,"price":0.15,"value":7500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold."}],"balance_after":530905,"source":{"system":"sec-edgar","filing":"0000899243-23-004233","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924323004233/doc4a.xml","form_type":"4/A","original_submission_date":"2023-02-07"}},{"id":2032124,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-03T23:12:08.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":50000,"price":36.8,"value":1840000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":430905,"source":{"system":"sec-edgar","filing":"0000899243-23-003921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924323003921/doc4.xml","form_type":"4"}},{"id":2225309,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T08:33:07.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being made to show the correct price of $3.00. An incorrect price of $2.99 was previously reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":8333,"derivative":{"exercise_price":3,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001104659-22-072752","document":"tm2218796-5_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922072752/tm2218796-5_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-06-09"}},{"id":2237674,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-09T17:59:17.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":8333,"derivative":{"exercise_price":2.99,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001104659-22-069758","document":"tm2218033-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922069758/tm2218033-5_4seq1.xml","form_type":"4"}},{"id":2246960,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-02T21:29:33.000Z","date":"2022-06-01","kind":"sale","acquired":false,"shares":30000,"price":12.2,"value":366000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.01 to $12.61. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":480905,"source":{"system":"sec-edgar","filing":"0000899243-22-020717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322020717/doc4.xml","form_type":"4"}},{"id":2281761,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-04T21:23:11.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":30000,"price":13.04,"value":391200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.69 to $13.75. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":510905,"source":{"system":"sec-edgar","filing":"0000899243-22-016657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322016657/doc4.xml","form_type":"4"}},{"id":2303481,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:09:03.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":3600,"price":18.93,"value":68148.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.64 to $19.16. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":540905,"source":{"system":"sec-edgar","filing":"0000899243-22-013858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322013858/doc4.xml","form_type":"4"}},{"id":2303480,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-05T22:09:03.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":26400,"price":18.92,"value":499488.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.34 to $19.43. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":544505,"source":{"system":"sec-edgar","filing":"0000899243-22-013858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322013858/doc4.xml","form_type":"4"}},{"id":2352771,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:48:31.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":11106,"price":17.36,"value":192800.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.05 to $18.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":570905,"source":{"system":"sec-edgar","filing":"0000899243-22-009096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322009096/doc4.xml","form_type":"4"}},{"id":2352770,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:48:31.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":18894,"price":17.82,"value":336691.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.62 to $18.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":582011,"source":{"system":"sec-edgar","filing":"0000899243-22-009096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322009096/doc4.xml","form_type":"4"}},{"id":2412967,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T23:11:27.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":280000,"derivative":{"exercise_price":18.51,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000899243-22-004665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322004665/doc4.xml","form_type":"4"}},{"id":2412966,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-03T23:11:27.000Z","date":"2022-02-03","kind":"sale","acquired":false,"shares":909,"price":19.16,"value":17416.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":600905,"source":{"system":"sec-edgar","filing":"0000899243-22-004665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322004665/doc4.xml","form_type":"4"}},{"id":2412965,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-03T23:11:27.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":12340,"price":18.47,"value":227919.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":601814,"source":{"system":"sec-edgar","filing":"0000899243-22-004665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322004665/doc4.xml","form_type":"4"}},{"id":2412964,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief  Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-03T23:11:27.000Z","date":"2022-02-01","kind":"sale","acquired":false,"shares":16751,"price":19.55,"value":327482.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":614154,"source":{"system":"sec-edgar","filing":"0000899243-22-004665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924322004665/doc4.xml","form_type":"4"}},{"id":2476783,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2021-12-10T23:08:09.000Z","date":"2021-12-08","kind":"exercise","acquired":false,"shares":9413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":627564},"source":{"system":"sec-edgar","filing":"0000899243-21-047801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924321047801/doc4.xml","form_type":"4"}},{"id":2476782,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-10T23:08:09.000Z","date":"2021-12-08","kind":"exercise","acquired":true,"shares":627564,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":630905,"source":{"system":"sec-edgar","filing":"0000899243-21-047801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924321047801/doc4.xml","form_type":"4"}},{"id":2561912,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-22T17:00:52.000Z","date":"2021-09-20","kind":"other","acquired":true,"shares":263321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 20, 2021, Lazarus Life Sciences I, LLC (\"Lazarus\"), a limited liability company in which the Reporting Person holds a profits interest, distributed all of its shares of common stock of the Issuer to its beneficial owners, including 263,321 shares of common stock to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities held by Lazarus, except to the extent of his pecuniary interest therein. All share numbers herein give effect to the one-for-six reverse stock split effected by the Issuer on August 19, 2021."}],"balance_after":263321,"source":{"system":"sec-edgar","filing":"0001104659-21-118359","document":"tm2128174-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465921118359/tm2128174-1_4seq1.xml","form_type":"4"}},{"id":2561911,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-22T17:00:52.000Z","date":"2021-09-20","kind":"other","acquired":false,"shares":263321,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Lazarus Life Sciences I, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 20, 2021, Lazarus Life Sciences I, LLC (\"Lazarus\"), a limited liability company in which the Reporting Person holds a profits interest, distributed all of its shares of common stock of the Issuer to its beneficial owners, including 263,321 shares of common stock to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities held by Lazarus, except to the extent of his pecuniary interest therein. All share numbers herein give effect to the one-for-six reverse stock split effected by the Issuer on August 19, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On September 20, 2021, Lazarus Life Sciences I, LLC (\"Lazarus\"), a limited liability company in which the Reporting Person holds a profits interest, distributed all of its shares of common stock of the Issuer to its beneficial owners, including 263,321 shares of common stock to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities held by Lazarus, except to the extent of his pecuniary interest therein. All share numbers herein give effect to the one-for-six reverse stock split effected by the Issuer on August 19, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-118359","document":"tm2128174-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465921118359/tm2128174-1_4seq1.xml","form_type":"4"}},{"id":2686341,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T19:17:33.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2021 and is schedule to vest in equal annual installments over a three-year period from the date of grant, subject to the director's continued service."}],"balance_after":85000,"derivative":{"exercise_price":2.04,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001104659-21-075909","document":"tm2118270-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465921075909/tm2118270-9_4seq1.xml","form_type":"4"}},{"id":2888520,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T21:56:21.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 28, 2021 and is scheduled to vest as to one-third of the common stock underlying the option on each anniversary of the grant date until the third anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.43,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-004013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000089924321004013/doc4.xml","form_type":"4"}},{"id":2901587,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-20T20:48:24.000Z","date":"2021-01-18","kind":"grant","acquired":true,"shares":800075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over the following 4 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":800075,"derivative":{"exercise_price":23.03,"expiration_date":"2031-01-17","underlying":"Common Stock","underlying_shares":800075},"source":{"system":"sec-edgar","filing":"0000899243-21-002484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924321002484/doc4.xml","form_type":"4"}},{"id":2997182,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2020-10-30T22:57:20.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":9413,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. (\"Merger\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. (\"Merger\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations."}],"balance_after":9413,"derivative":{"underlying":"Common Stock","underlying_shares":9413000},"source":{"system":"sec-edgar","filing":"0000899243-20-029996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924320029996/doc4.xml","form_type":"4"}},{"id":2997181,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-10-30T22:57:20.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":4338079,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. (\"Merger\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for an employee stock option to acquire 392,857 shares of Viridian Therapeutics, Inc. common stock for $0.03 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":4338079,"derivative":{"exercise_price":0.01,"expiration_date":"2030-09-23","underlying":"Common Stock","underlying_shares":4338079},"source":{"system":"sec-edgar","filing":"0000899243-20-029996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924320029996/doc4.xml","form_type":"4"}},{"id":2997180,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2020-10-30T22:57:20.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":50124,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. (\"Merger\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. (\"Merger\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock."}],"balance_after":50124,"source":{"system":"sec-edgar","filing":"0000899243-20-029996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924320029996/doc4.xml","form_type":"4"}},{"id":4019784,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Scientific Affairs & IR"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-02T22:25:09.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable on an annual basis (every twelve months) from the Transaction Date listed above, with respect to one-half of the total number of shares subject to the option, in each case subject to the reporting person's Continuous Service (as defined in the 2013 Equity Incentive Plan, as amended) as of each such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.79,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-18-015856","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919118015856/doc4.xml","form_type":"4"}},{"id":4019783,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":41673,"kind":"person","name":"Violin Jonathan","position":1,"cik":"0001730615","reported_name":"Violin Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-Scientific Affairs & IR"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-02T22:25:09.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.79,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-015856","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000120919118015856/doc4.xml","form_type":"4"}}]}